At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
Mesdopetam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating Mesdopetam and Placebo for Parkinson Disease. Completed, enrolled 155 participants across 44 sites in 6 countries.
Detailed Summary
This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesFrance, Israel, Italy, Poland, Serbia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartOct 2020
Primary CompletionDec 2022
Study CompletionDec 2022
TodayJul 2026
First PostedJun 17, 2020
Enrollment StartOct 29, 2020
Primary CompletionDec 2, 2022
Study CompletionDec 9, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.0 years ago
Interventions
Mesdopetamdrug
Oral use
Placebodrug
Oral use